Showing 4521-4530 of 5627 results for "".
- Oculus and Myopia Profile Aim to Increase Knowledge on Myopiahttps://modernod.com/news/oculus-and-myopia-profile-aim-to-increase-knowledge-on-myopia/2478860/Myopia Profile and Oculus have commenced a partnership to increase ECP knowledge and clinical confidence in measurement and interpretation of axial length in myopia. Specific educational content, research summaries and case studies will be developed, to be housed on MyopiaProfile.com and shared a
- Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry AMD in Patients with High-Risk Genetic Variantshttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-trial-of-gem103-in-dry-amd-in-patients-with-high-risk-genetic-variants/2478851/Gemini Therapeutics announced the completion of enrollment in its phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safet
- Medicom Healthcare Signs Asset Purchase Agreement of Bimatoprost 0.3 mg/mL, 3mlhttps://modernod.com/news/medicom-healthcare-signs-asset-purchase-agreement-of-bimatoprost-0-3-mg-ml-3ml/2478852/Medicom Healthcare and Famar Health Care Services Madrid have announced the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of Bimatorost 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement
- Euclid Systems Announces Expansion of Leadership Teamhttps://modernod.com/news/euclid-systems-announces-expansion-of-leadership-team/2478845/Euclid Systems has announced expansion of its leadership team. Joseph Boorady, OD, FAAO, appointed to the position of president and chief executive officer in January 2020, brings over 25 years of experience in the ophthalmic industry as an eye care professional, educational leader, entrepreneur
- Roche Files for FDA Emergency Use Authorization for SARS-CoV-2 Rapid Antigen Testhttps://modernod.com/news/roche-files-for-fda-emergency-use-authorization-for-sars-cov-2-rapid-antigen-test/2478844/Roche announced it has submitted for FDA Emergency Use Authorization (EUA) for a SARS-CoV-2 Rapid Antigen Test that is designed for use by health care professionals in point-of-care settings with patients experiencing symptoms of COVID-19. The test is designed to help health care professi
- jCyte Promotes Dr. Shannon Blalock to Chief Executive Officerhttps://modernod.com/news/jcyte-promotes-dr-shannon-blalock-to-chief-executive-officer/2478840/jCyte announced the Board of Directors has promoted Shannon Blalock, PharmD, to Chief Executive Officer, and an elected member of the Board. Dr. Blalock joined jCyte last year as its Chief Operating Officer. “I am thrilled to announce the appointment of Shannon as jCyte’s new CEO at this i
- Santen Launches Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-launches-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2478828/Santen EMEA has announced the launch of Ducressa, a fixed dose combination of levofloxacin/dexamethasone eye drops solution indicated for the prevention and treatment of inflammation, and the prevention of infection a
- Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technologyhttps://modernod.com/news/turn-biotechnologies-expands-the-potential-of-its-mrna-platform-by-licensing-unique-artificial-niche-technology/2478826/Turn Biotechnologies announced that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging. Terms of the deal were not disclosed. The company licensed its AN technology from Stanf
- Inflammasome Therapeutics Says Study Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-says-study-provides-human-data-confirming-potential-of-companys-proprietary-compounds-for-prevention-of-dry-amd/2478824/Inflammasome Therapeutics reported that data analyses published in the current issue of Proceedings of the National Academy of Sciences (PNAS) confirms that the company’s proprietary compounds hold significant promise in the prevention and treatment of dry age-related macular degeneration
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b